Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dominantly Inherited Alzheimer Network (DIAN) – Spanish FDG/PIB PET Safety and Registry Study
2018-002319-86Phase 4Active
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Nov 2018
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Positron Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fludeoxyglucose f 18 and carbon-11 Pittsburgh compound B in Alzheimer's disease (AD), sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoint: Incidence of adverse events after [18F] FDG and [11C] PIB administration. Started Nov 2018; status: active.
02
Drugs
fludeoxyglucose f 18carbon-11 Pittsburgh compound B
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2018-002319-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002319-86.